Skip to main content

Table 1 Activity of ca603 and pleconaril against representative viruses from HRV-A and B; and EV-A,-B and-C

From: In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses

Virus strain

EC50 (ca603) (μM)

EC50 (pleconaril) (μM)

HRV-A

HRV02

>313

0.2 ± 0.1*

HRV09

8.9 ± 4.2*

0.2 ± 0.1*

HRV29

1.7 ± 0.04*

0.1 ± 0.1*

HRV63

>157

0.1 ± 0.1*

HRV85

3.7 ± 2.0*

0.1 ± 0.1*

HRV89

0.9 ± 0.8*

0.7 ± 0.3*

HRV-B

HRV14

0.10 ± 0.03*

0.3 ± 0.2*

HRV42

8.2 ± 4.7

>26

HRV70

15 ± 8*

4 ± 3.6

HRV86

0.01 ± 0.003*

0.1 ± 0.1*

EV-A

EV71

74 ± 5

>52

EV-B

CVB3

>313

>131

EV-B

ECHO11

2.5 ± 1.6

1.7 ± 0.4

EV-C

PV1

25 ± 7

>131

  1. Antiviral activity was determined in a CPE reduction assay with MTS read-out. EC50 = median 50 % effective concentration ± MAD from dose response curves set up from ≥ four experiments of which at least two independent. * = 100 % inhibition of virus-induced cytopathic effect can be achieved with this compound (as determined by microscopic inspection). CC50 HeLa = 153 ± 19 μM; CC50 BGM = 171 ± 16 μM; CC50 RD = 221 ± 28 µM